Open AccessEffects of the P‐Selectin Antagonist Inclacumab on Myocardial Damage After Percutaneous Coronary Intervention According to Timing of Infusion: Insights From the SELECT ‐ ACS Trial
Author(s) -
Stähli Barbara E.,
Gebhard Catherine,
Duchatelle Valérie,
Cournoyer Daniel,
Petroni Thibaut,
Tanguay JeanFrançois,
Robb Stephen,
Mann Jessica,
Guertin MarieClaude,
Wright R. Scott,
L. L'Allier Philippe,
Tardif JeanClaude
Publication year - 2016
Publication title -
journal of the american heart association
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.494
H-Index - 85
ISSN - 2047-9980
DOI - 10.1161/jaha.116.004255
Subject(s) - medicine , conventional pci , percutaneous coronary intervention , myocardial infarction , cardiology , creatine kinase , placebo , troponin t , troponin i , troponin , anesthesia , alternative medicine , pathology
The Effects of the P-Selectin Antagonist Inclacumab on Myocardial Damage After Percutaneous Coronary Intervention for Non-ST-Segment Elevation Myocardial Infarction (SELECT-ACS) trial suggested beneficial effects of inclacumab, a monoclonal antibody directed against P-selectin, on periprocedural myocardial damage. This study evaluated the effect of inclacumab on myocardial damage according to varying time intervals between study drug infusion and percutaneous coronary intervention (PCI).